Anne M Murray1,2, Fang-Chi Hsu3, Jeff D Williamson4, R Nick Bryan5, Hertzel C Gerstein6,7, Mark D Sullivan8, Michael E Miller3, Iris Leng3, Laura L Lovato3, Lenore J Launer9. 1. Division of Geriatrics, Department of Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis, MN, USA. amurray@bermancenter.org. 2. Berman Center for Clinical Research, Hennepin County Medical Center, 701 Park Avenue, Suite PPC4-440, Minneapolis, MN, 55415, USA. amurray@bermancenter.org. 3. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston Salem, NC, USA. 4. Geriatic Medicine, Department of Internal Medicine, J. Paul Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest School of Medicine, Winston Salem, NC, USA. 5. Department of Radiology, University of Pennsylvania Health System, Philadelphia, PA, USA. 6. Department of Medicine, McMaster University, Hamilton, ON, Canada. 7. Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada. 8. Department of Psychiatry and Behavioural Sciences, University of Washington, Seattle, WA, USA. 9. Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, MD, USA.
Abstract
AIMS/HYPOTHESIS: The Memory in Diabetes (MIND) substudy of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, a double 2x2 factorial parallel-group randomised clinical trial, tested whether intensive compared with standard management of hyperglycaemia, BP or lipid levels reduced cognitive decline and brain atrophy in 2977 people with type 2 diabetes. We describe the results of the observational extension study, ACCORDION MIND (ClinicalTrials.gov registration no. NCT00182910), which aimed to measure the long-term effects of the three ACCORD interventions on cognitive and brain structure outcomes approximately 4 years after the trial ended. METHODS:Participants (mean diabetes duration 10 years; mean age 62 years at baseline) received afourth cognitive assessment and a third brain MRI, targeted at 80 months post-randomisation. Primary outcomes were performance on the Digit Symbol Substitution Test (DSST) and total brain volume (TBV). The contrast of primary interest compared glycaemic intervention groups at the ACCORDION visit; secondary contrasts were the BP and lipid interventions. RESULTS: Of the surviving ACCORD participants eligible for ACCORDION MIND, 1328 (68%) were re-examined at the ACCORDION follow-up visit, approximately 47 months after the intensive glycaemia intervention was stopped. The significant differences in therapeutic targets for each of the three interventions (glycaemic, BP and lipid) were not sustained. We found no significant difference in 80 month mean change from baseline in DSST scores or in TBV between the glycaemic intervention groups, or the BP and lipid interventions. Sensitivity analyses of the sites with ≥70% participation at 80 months revealed consistent results. CONCLUSIONS/ INTERPRETATION: The ACCORD interventions did not result in long-term beneficial or adverse effects on cognitive or brain MRI outcomes at approximately 80 months follow-up. Loss of separation in therapeutic targets between treatment arms and loss to follow-up may have contributed to the lack of detectable long-term effects. TRIAL REGISTRATION: ClinicalTrials.gov NCT00182910.
RCT Entities:
AIMS/HYPOTHESIS: The Memory in Diabetes (MIND) substudy of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, a double 2x2 factorial parallel-group randomised clinical trial, tested whether intensive compared with standard management of hyperglycaemia, BP or lipid levels reduced cognitive decline and brain atrophy in 2977 people with type 2 diabetes. We describe the results of the observational extension study, ACCORDION MIND (ClinicalTrials.gov registration no. NCT00182910), which aimed to measure the long-term effects of the three ACCORD interventions on cognitive and brain structure outcomes approximately 4 years after the trial ended. METHODS:Participants (mean diabetes duration 10 years; mean age 62 years at baseline) received a fourth cognitive assessment and a third brain MRI, targeted at 80 months post-randomisation. Primary outcomes were performance on the Digit Symbol Substitution Test (DSST) and total brain volume (TBV). The contrast of primary interest compared glycaemic intervention groups at the ACCORDION visit; secondary contrasts were the BP and lipid interventions. RESULTS: Of the surviving ACCORD participants eligible for ACCORDION MIND, 1328 (68%) were re-examined at the ACCORDION follow-up visit, approximately 47 months after the intensive glycaemia intervention was stopped. The significant differences in therapeutic targets for each of the three interventions (glycaemic, BP and lipid) were not sustained. We found no significant difference in 80 month mean change from baseline in DSST scores or in TBV between the glycaemic intervention groups, or the BP and lipid interventions. Sensitivity analyses of the sites with ≥70% participation at 80 months revealed consistent results. CONCLUSIONS/ INTERPRETATION: The ACCORD interventions did not result in long-term beneficial or adverse effects on cognitive or brain MRI outcomes at approximately 80 months follow-up. Loss of separation in therapeutic targets between treatment arms and loss to follow-up may have contributed to the lack of detectable long-term effects. TRIAL REGISTRATION: ClinicalTrials.gov NCT00182910.
Entities:
Keywords:
Abnormal white matter volume; Brain MRI; Cognitive impairment; Total brain volume; Type 2 diabetes
Authors: Zhiqiang Lao; Dinggang Shen; Dengfeng Liu; Abbas F Jawad; Elias R Melhem; Lenore J Launer; R Nick Bryan; Christos Davatzikos Journal: Acad Radiol Date: 2008-03 Impact factor: 3.173
Authors: Catherine L Martin; Barbara H Waberski; Rodica Pop-Busui; Patricia A Cleary; Sarah Catton; James W Albers; Eva L Feldman; William H Herman Journal: Diabetes Care Date: 2010-09-10 Impact factor: 19.112
Authors: Neil H White; Wanjie Sun; Patricia A Cleary; Ronald P Danis; Matthew D Davis; Dean P Hainsworth; Larry D Hubbard; John M Lachin; David M Nathan Journal: Arch Ophthalmol Date: 2008-12
Authors: M W Vernooij; M de Groot; A van der Lugt; M A Ikram; G P Krestin; A Hofman; W J Niessen; M M B Breteler Journal: Neuroimage Date: 2008-08-08 Impact factor: 6.556
Authors: Reinhold Schmidt; Lenore J Launer; Lars-Göran Nilsson; Andrzej Pajak; Susanna Sans; Klaus Berger; Monique M Breteler; Maria de Ridder; Carole Dufouil; Rebecca Fuhrer; Simona Giampaoli; Albert Hofman Journal: Diabetes Date: 2004-03 Impact factor: 9.461
Authors: C Jongen; J van der Grond; L J Kappelle; G J Biessels; M A Viergever; J P W Pluim Journal: Diabetologia Date: 2007-05-11 Impact factor: 10.122
Authors: Bernhard Haring; Xiaoyan Leng; Jennifer Robinson; Karen C Johnson; Rebecca D Jackson; Rebecca Beyth; Jean Wactawski-Wende; Moritz Wyler von Ballmoos; Joseph S Goveas; Lewis H Kuller; Sylvia Wassertheil-Smoller Journal: J Am Heart Assoc Date: 2013-12-18 Impact factor: 5.501
Authors: Boris Draznin; Vanita R Aroda; George Bakris; Gretchen Benson; Florence M Brown; RaShaye Freeman; Jennifer Green; Elbert Huang; Diana Isaacs; Scott Kahan; Jose Leon; Sarah K Lyons; Anne L Peters; Priya Prahalad; Jane E B Reusch; Deborah Young-Hyman Journal: Diabetes Care Date: 2022-01-01 Impact factor: 19.112
Authors: Jackson T Wright; Paul K Whelton; Karen C Johnson; Joni K Snyder; David M Reboussin; William C Cushman; Jeff D Williamson; Nicholas M Pajewski; Alfred K Cheung; Cora E Lewis; Suzanne Oparil; Michael V Rocco; Srinivasan Beddhu; Lawrence J Fine; Jeffrey A Cutler; Walter T Ambrosius; Mahboob Rahman; Carolyn H Still; Zhengyi Chen; Curtis Tatsuoka Journal: Hypertension Date: 2021-11-10 Impact factor: 10.190
Authors: Ilya M Nasrallah; Nicholas M Pajewski; Alexander P Auchus; Gordon Chelune; Alfred K Cheung; Maryjo L Cleveland; Laura H Coker; Michael G Crowe; William C Cushman; Jeffrey A Cutler; Christos Davatzikos; Lisa Desiderio; Jimit Doshi; Guray Erus; Larry J Fine; Sarah A Gaussoin; Darrin Harris; Karen C Johnson; Paul L Kimmel; Manjula Kurella Tamura; Lenore J Launer; Alan J Lerner; Cora E Lewis; Jennifer Martindale-Adams; Claudia S Moy; Linda O Nichols; Suzanne Oparil; Paula K Ogrocki; Mahboob Rahman; Stephen R Rapp; David M Reboussin; Michael V Rocco; Bonnie C Sachs; Kaycee M Sink; Carolyn H Still; Mark A Supiano; Joni K Snyder; Virginia G Wadley; Jennifer Walker; Daniel E Weiner; Paul K Whelton; Valerie M Wilson; Nancy Woolard; Jackson T Wright; Clinton B Wright; Jeff D Williamson; R Nick Bryan Journal: JAMA Date: 2019-08-13 Impact factor: 56.272
Authors: Adam de Havenon; Jennifer J Majersik; David L Tirschwell; J Scott McNally; Gregory Stoddard; Natalia S Rost Journal: Neurology Date: 2019-02-08 Impact factor: 9.910